Celgene Sues Barr Over Generic Thalomid

Law360, New York (August 27, 2007, 12:00 AM EDT) -- Celgene Corp. has filed another patent suit against Barr Pharmaceuticals Inc. in an attempt to stave off generic competition for its lucrative cancer treatment Thalomid, which brought in $117.7 million in net sales in the second quarter of 2007.

Celgene filed the lawsuit Thursday in the U.S. District Court for the District of New Jersey, naming Barr Laboratories Inc. and Barr Pharmaceuticals Inc. as defendants. Celgene had already sued Barr over Thalomid in January, but Thursday's suit accuses Barr of infringing U.S. Patent Number 7,230,012, which...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.